SP today, page-55

TA or FA, I think most would have to agree that the price of all speculative biotech stocks are announcement driven... so why not give some consideration to what the company has already advised the market:

* European license for Manufacturing Q1-Q2 2011
* Registration study recruitment commencement June 2011
* FDA meeting for registration study review Q3 2011
* Completion of CAN-003 phase IIb recruitment June 2011
* Cripto 1 mAB feasibility Q2 2011
* Oral HPV vaccine initial data Q2 2011

Imo, there is also now a reasonably good indication that Prima will announce SEC Form 10 effective for Nasdaq listing between June 14-24.

Also worth considering the Investor Update presented quarterly with the next anticipated to be this Wednesday June 8.
__________

Hi Boiler,

Abagovomab led to a formation of antibodies against the tumour in 70 % of patients

With CVac, 100% of patients produced the desired cellular immune response.

Imo, even if both treatments were to pass all the neccessary regularity hurdles to commercialize within their applied jurisdictions there will still be plenty of space for two companies to prosper very well in this unmet therapy market.

Prima have set their initial target for only 10% of the $3.6 billion market.